MIRA: AI 评分 46/100 — AI 分析 (4月 2026)

MIRA Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing MIRA1a, a synthetic THC analog, for treating anxiety and cognitive decline associated with early-stage dementia. The company targets cannabinoid receptors to address anxiety and chronic pain.

Key Facts: Price: $1.02 AI Score: 46/100 Sector: Healthcare

公司概况

概要：

MIRA Pharmaceuticals offers a notable market position in the biopharmaceutical sector, developing MIRA1a, a novel synthetic THC analog, targeting a significant unmet need in anxiety and cognitive decline associated with early-stage dementia, positioning them for substantial growth in the cannabinoid therapeutics market.

MIRA是做什么的？

MIRA Pharmaceuticals, Inc., incorporated in 2020 and headquartered in Baltimore, Maryland, is a clinical development stage biopharmaceutical company dedicated to addressing critical unmet needs in neurological disorders. The company's primary focus is the development and commercialization of MIRA1a, a novel synthetic tetrahydrocannabinol (THC) analog. This innovative compound is under investigation for the treatment of adult patients suffering from anxiety and cognitive decline, conditions frequently associated with the early stages of dementia. MIRA1a is designed to target both cannabinoid type 1 (CB1) and cannabinoid type 2 (CB2) receptors, offering a dual-action approach to alleviate anxiety and manage chronic pain. Formerly known as MIRA1a Therapeutics, Inc., the company is committed to rigorous clinical trials and regulatory processes to bring this potential therapeutic to market. MIRA's strategic focus on synthetic cannabinoids allows for precise control over dosage and formulation, potentially overcoming some of the challenges associated with naturally derived cannabis products. With a lean operational structure and a clear clinical pathway, MIRA Pharmaceuticals aims to establish itself as a key player in the emerging field of cannabinoid-based pharmaceuticals.

MIRA的投资论点是什么？

MIRA Pharmaceuticals presents a notable market position due to its focused approach on developing MIRA1a, a synthetic THC analog, to address the growing market for anxiety and cognitive decline treatments. The company's strategy of targeting both CB1 and CB2 receptors offers a unique mechanism of action with the potential for improved efficacy and reduced side effects compared to existing treatments. The current market capitalization of $0.05 billion, coupled with a high beta of 1.82, suggests significant growth potential if MIRA1a achieves positive clinical trial results. Key value drivers include successful completion of clinical trials, strategic partnerships, and eventual commercialization of MIRA1a. Upcoming clinical trial milestones represent significant catalysts for stock appreciation. The absence of a dividend allows the company to reinvest earnings into research and development, further fueling growth.

MIRA在哪个行业运营？

MIRA Pharmaceuticals operates within the drug manufacturers industry, a segment of the broader healthcare sector. The market for anxiety and cognitive decline treatments is substantial and growing, driven by an aging population and increasing awareness of mental health issues. The competitive landscape includes both traditional pharmaceutical companies and emerging biotech firms focused on cannabinoid-based therapies. MIRA's focus on synthetic cannabinoids offers a potential advantage in terms of consistency and regulatory compliance. The industry is characterized by high R&D costs, lengthy regulatory approval processes, and intense competition.

Drug Manufacturers - General

Healthcare

MIRA有哪些增长机遇？

Advancement of MIRA1a through Clinical Trials: A primary growth opportunity lies in successfully navigating the clinical trial process for MIRA1a. Positive results from Phase I, II, and III trials will significantly increase the company's valuation and attract potential partnerships. The market for dementia and anxiety treatments is projected to reach billions of dollars by 2030, offering a substantial revenue opportunity if MIRA1a proves effective and safe. Timeline: Ongoing clinical trials with data readouts expected in the next 12-24 months.
Strategic Partnerships and Licensing Agreements: MIRA Pharmaceuticals can pursue strategic partnerships with larger pharmaceutical companies to accelerate the development and commercialization of MIRA1a. Licensing agreements can provide upfront payments, milestone payments, and royalties, generating significant revenue streams. The global pharmaceutical licensing market is estimated to be worth hundreds of billions of dollars annually. Timeline: Potential partnerships can be established within the next 12-18 months following positive clinical trial data.
Expansion of Pipeline with New Cannabinoid Analogs: MIRA can leverage its expertise in synthetic cannabinoid development to expand its pipeline with new drug candidates targeting other neurological and pain-related disorders. This diversification will reduce the company's reliance on MIRA1a and create additional growth opportunities. The market for pain management drugs is substantial and growing, driven by an aging population and increasing prevalence of chronic pain conditions. Timeline: New drug candidates can be identified and developed within the next 2-3 years.
Securing Orphan Drug Designation: Pursuing orphan drug designation for MIRA1a in specific rare dementia subtypes can provide significant regulatory and financial benefits, including market exclusivity and tax credits. This strategy can enhance the commercial attractiveness of MIRA1a and accelerate its adoption by healthcare providers. The orphan drug market is a rapidly growing segment of the pharmaceutical industry. Timeline: Orphan drug designation can be pursued within the next 6-12 months based on clinical data and regulatory guidelines.
Geographic Expansion into International Markets: MIRA Pharmaceuticals can expand its market reach by seeking regulatory approval for MIRA1a in international markets, such as Europe and Asia. This will significantly increase the company's potential customer base and revenue opportunities. The global market for dementia and anxiety treatments is substantial, with significant growth potential in emerging markets. Timeline: International expansion can be pursued within the next 3-5 years following successful commercialization in the United States.

MIRA Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing MIRA1a.
MIRA1a is a synthetic THC analog targeting anxiety and cognitive decline associated with early-stage dementia.
The company targets cannabinoid type 1 and type 2 receptors to treat anxiety and chronic pain.
MIRA Pharmaceuticals has a market capitalization of $0.05 billion.
The company operates with a lean team of 2 employees, indicating a focus on efficient resource allocation.

MIRA提供哪些产品和服务？

Develops synthetic tetrahydrocannabinol (THC) analogs.
Focuses on treatments for anxiety and cognitive decline.
Targets cannabinoid type 1 (CB1) and type 2 (CB2) receptors.
Conducts clinical trials to evaluate the safety and efficacy of MIRA1a.
Aims to commercialize MIRA1a for the treatment of adult patients with early-stage dementia.
Researches and develops new cannabinoid-based therapies.

MIRA如何赚钱？

Develop and patent novel synthetic cannabinoid analogs.
Conduct preclinical and clinical trials to demonstrate safety and efficacy.
Seek regulatory approval from the FDA for commercialization.
Partner with pharmaceutical companies for manufacturing and distribution, or establish in-house capabilities.

Adult patients suffering from anxiety and cognitive decline associated with early-stage dementia.
Healthcare providers, including physicians and psychiatrists, who prescribe treatments for these conditions.
Pharmacies and hospitals that dispense and administer the medication.
Potential pharmaceutical partners seeking to license or acquire MIRA1a.

Proprietary synthetic cannabinoid analogs with patent protection.
Targeting a specific unmet need in anxiety and cognitive decline associated with early-stage dementia.
Dual-action approach targeting both CB1 and CB2 receptors.
Experienced management team with expertise in drug development and commercialization.

什么因素可能推动MIRA股价上涨？

Upcoming: Announcement of Phase I clinical trial results for MIRA1a (expected within the next 6-12 months).
Upcoming: Initiation of Phase II clinical trials for MIRA1a in patients with early-stage dementia (expected within the next 12-18 months).
Ongoing: Progress in securing strategic partnerships with pharmaceutical companies.
Ongoing: Expansion of the company's intellectual property portfolio through new patent filings.
Ongoing: Potential for securing orphan drug designation for MIRA1a.

MIRA的主要风险是什么？

Potential: Failure to obtain regulatory approval from the FDA for MIRA1a.
Potential: Unfavorable clinical trial results demonstrating lack of efficacy or safety concerns.
Potential: Competition from other companies developing similar treatments.
Ongoing: Dependence on securing additional funding to support clinical development activities.
Ongoing: Changes in the regulatory landscape regarding cannabinoid-based therapies.

MIRA的核心优势是什么？

Novel synthetic THC analog targeting a specific unmet need.
Dual-action mechanism targeting both CB1 and CB2 receptors.
Experienced management team.
Relatively low market capitalization, offering potential for high growth.

MIRA的劣势是什么？

Clinical-stage company with no currently approved products.
Limited financial resources.
High dependence on the success of MIRA1a.
Small team size.

MIRA有哪些机遇？

Positive clinical trial results for MIRA1a.
Strategic partnerships with larger pharmaceutical companies.
Expansion of pipeline with new cannabinoid analogs.
Securing orphan drug designation for specific dementia subtypes.

MIRA面临哪些威胁？

Failure to obtain regulatory approval for MIRA1a.
Competition from other companies developing similar treatments.
Changes in regulatory landscape regarding cannabinoid-based therapies.
Unfavorable clinical trial results.

MIRA的竞争对手是谁？

Antibe Therapeutics Inc. — Focuses on pain and inflammation treatments. — (ANTX)
Agenus Inc. — Develops immuno-oncology products. — (APUS)
India Globalization Capital, Inc. — Involved in cannabinoid-based products. — (IGC)
Milestone Scientific Inc. — Develops medical and dental technologies. — (MLSS)
Moderna, Inc. — Develops mRNA therapeutics and vaccines. — (MODD)

Key Metrics

Price: $1.02 (-3.77%)
Market Cap: $43.0M
MoonshotScore: 46/100

Company Profile

CEO: Erez Aminov
Headquarters: Baltimore, MD, US
Employees: 2
Founded: 2023

AI Insight

MIRA Pharmaceuticals, Inc. is a clinical development stage biopharmaceutical company focused on developing and commercializing a synthetic THC analog, MIRA1a, for the treatment of anxiety and cognitive decline associated with early-stage dementia. They are targeting cannabinoid type 1 and type 2 receptors to treat anxiety and chronic pain.

常见问题

What does MIRA Pharmaceuticals, Inc. do?

MIRA Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of MIRA1a, a synthetic tetrahydrocannabinol (THC) analog. Their primary focus is to address the unmet medical needs of patients suffering from anxiety and cognitive decline typically associated with early-stage dementia. MIRA1a is designed to target both cannabinoid type 1 (CB1) and cannabinoid type 2 (CB2) receptors, offering a potential therapeutic approach for anxiety and chronic pain management. The company is currently conducting clinical trials to evaluate the safety and efficacy of MIRA1a.

Is MIRA stock a good buy?

MIRA Pharmaceuticals presents a speculative investment opportunity, characterized by high risk and potentially high reward. The company's success hinges on the successful development and commercialization of MIRA1a. While the market for anxiety and cognitive decline treatments is substantial, MIRA faces significant competition and regulatory hurdles. The current P/E ratio of -0.82 reflects the company's lack of profitability. Investors should carefully consider their risk tolerance and conduct thorough due diligence before investing in MIRA stock. Positive clinical trial results and strategic partnerships could significantly increase the stock's value.

What are the main risks for MIRA?

The primary risks for MIRA Pharmaceuticals include the inherent uncertainties associated with clinical-stage drug development. Failure to obtain regulatory approval from the FDA for MIRA1a would be a significant setback. Unfavorable clinical trial results, demonstrating a lack of efficacy or safety concerns, could also negatively impact the company's prospects. Competition from other companies developing similar treatments poses another risk. Additionally, MIRA's dependence on securing additional funding to support its clinical development activities and potential changes in the regulatory landscape regarding cannabinoid-based therapies represent ongoing challenges.